“Brain Damage Is Possible Even After a Single Dose. The EMA Has Ordered the Immediate Recall of the Drugs.” — What’s the Story?
This headline refers to a specific medication, not to all medicines.
In 2026, the European Medicines Agency recommended withdrawing medicines containing levamisole from the EU market after a safety review found that they can, in rare cases, cause leukoencephalopathy—a serious condition that damages the brain’s white matter. The review found that this adverse effect can occur even after a single dose, although it is rare. (European Medicines Agency (EMA))
Which Drug Was Affected?
The recommendation applies to levamisole-containing medicines, which were used in some European countries to treat certain parasitic worm infections. Other treatments are available, and the EMA concluded that the benefits of levamisole no longer outweighed its risks for this use. (European Medicines Agency (EMA))
What Symptoms Were Reported?
People who develop levamisole-associated leukoencephalopathy may experience:
- Muscle weakness
- Difficulty speaking
- Confusion
- Problems with balance or coordination
- Cognitive changes
Symptoms may appear from one day to several months after taking the medicine. (European Medicines Agency (EMA))
Should You Be Concerned?
- If you have never taken levamisole, this announcement does not apply to you.
- Do not stop any prescribed medication because of a headline unless your healthcare professional advises you to do so.
- If you think you have taken a levamisole-containing medicine and develop concerning neurological symptoms, seek medical attention promptly. (European Medicines Agency (EMA))
Bottom Line
The headline is based on a real EMA safety action, but it is often presented without context. The warning concerns levamisole-containing medicines, not common medications in general, and the serious brain complication is rare, even though it can occur after a single dose. (European Medicines Agency (EMA))
